Specialty Pharmacy

The Cadillac tax will carry a 40% nondeductible excise tax on employer-based plans greater than $10,200 for individuals and $27,500 for families.

Federal law allows the FDA to shorten both the clinical trial and approval processes for a large number of prescription drugs.

A study found positive outcomes of dose-attenuated combination therapy with lenalidomide and dexamethasone plus bortezomib in multiple myeloma patients.

Immune checkpoint blockades have shown long-term control of different types of cancer.

PET scans are not recommended for long-term monitoring of cancer recurrence.

Expanded federal funding allows Department of Veterans Affairs to fund care for all veterans with hepatitis C.

The role of pharmacists in the treatment of acute coronary syndrome, COPD, atrial fibrillation, heart failure, opioid-induced constipation, and type 2 diabetes.

Study finds reducing inflammation carries the added benefit of improving cognition among patients with HIV.

Top stories of the week from The American Journal of Pharmacy Benefits.

Study suggests low dose chemotherapy that controls tumor growth instead of eradicating the disease may be a more effective long term treatment.

Recent advances and updates in oncology and cancer drug development.

Independent pharmacies are uniquely situated for personalized patient interactions.

Expanded use of crizotinib treats patients with ROS1-positive metastatic non–small cell lung cancer.

Starting in 2020, a 40% tax will be levied on employer plans in excess of $29,000 for family coverage and $10,700 for individual coverage.

Special considerations must be made when treating patients infected with both HIV and hepatitis C virus.

Sarilumab shows superiority to adalimumab treating the signs and symptoms of active rheumatoid arthritis.

Sanofi and Regeneron Pharmaceuticals announce results of phase 3 trial showing efficacy of sarilumab in improving the signs and symptoms of active rheumatoid arthritis.

New proposed plan designs would give first-dollar coverage for all prescription drugs in the silver and gold plans.

Most read articles of the week on Specialty Pharmacy Times.

The cost of treating pediatric cancer can force higher-income families into poverty.

Harnessing T cells may lead to significant new cancer treatments.

MiRNA is a small non-coding RNA molecule that plays a role in the regulation of gene expression.

Beaming of X-rays at immobilized molecules could lead to new methods to fight HIV and retrovirus-based cancers.

Researchers evaluate fingolimod (Gilenya) in patients with highly active relapsing remitting multiple sclerosis.

Biosimilars face scrutiny before they can be indicated for inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis.

Average percentage of covered drugs with coinsurance jumped from 35% in 2014 to 58% in 2016, leading to higher out-of-pocket costs.

Electronic health records and e-prescribing allow for electronic refill submissions to ease the burden on care providers.

New approach could prevent bone loss induced by antiretroviral therapy in HIV patients.